tbuckley/cabot-search huggingface dataset:
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI
Authors: Justin E. Davies, Sayan Sen, Hakim-Moulay Dehbi, Rasha Al-Lamee, Ricardo Petraco, Sukhjinder S. Nijjer, Ravinay Bhindi, Sam J. Lehman, Darren Walters, James Sapontis, Luc Janssens, Christiaan J. Vrints, Ahmed Khashaba, Mika Laine, Eric Van Belle, Florian Krackhardt, Waldemar Bojara, Olaf Going, Tobias Härle, Ciro Indolfi, Giampaolo Niccoli, Flavo Ribichini, Nobuhiro Tanaka, Hiroyoshi Yokoi, Hiroaki Takashima, Yuetsu Kikuta, Andrejs Erglis, Hugo Vinhas, Pedro Canas Silva, Sérgio B. Baptista, Ali Alghamdi, Farrel Hellig, Bon-Kwon Koo, Chang-Wook Nam, Eun-Seok Shin, Joon-Hyung Doh, Salvatore Brugaletta, Eduardo Alegria-Barrero, Martijin Meuwissen, Jan J. Piek, Niels van Royen, Murat Sezer, Carlo Di Mario, Robert T. Gerber, Iqbal S. Malik, Andrew S.P. Sharp, Suneel Talwar, Kare Tang, Habib Samady, John Altman, Arnold H. Seto, Jasvindar Singh, Allen Jeremias, Hitoshi Matsuo, Rajesh K. Kharbanda, Manesh R. Patel, Patrick Serruys, Javier Escaned
Journal: New England Journal of Medicine (2017)

Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR.
Emergency diagnosis of lung cancer: An international problem.
Authors: Thomas Newsom-Davis, Rossana Berardi, Norah Cassidy, Linda Coate, Ana Figueiredo, Gabriele Gamerith, Gareth Giblin, Marko Jakopović, Cor Van Der Leest, Damien Pouessel, Marcello Tiseo, Anne Claire Toffart, Cathy Hughes
Journal: Journal of Clinical Oncology (2015)

6536 Background: Lung cancer survival in the United Kingdom (UK) is lower than similar healthcare systems in Europe. 40% of UK lung cancer patients are first diagnosed with their disease during presentation to emergency or acute medical services. This emergency presentation (EP) is associated with late diagnosis and lower 1-year relative survival. The gatekeeper role of the general practitioner (GP) has been suggested as a possible cause for the high rates of EP in the UK. We investigated whether EP is a feature of other healthcare systems in Europe. Methods: Retrospective data was collected on all lung cancer patients diagnosed in 2012 from 11 hospitals in 8 countries: Austria, Croatia, France, Ireland, Italy, Netherlands, Portugal and UK. Where required, ethical approval was obtained prior to data collection. Results: 2,315 patients were included, of which 534 (23.1%) were diagnosed as part of an emergency presentation. EP rates between counties ranged from 13.2% to 47.7% and did not correlate with whether GPs act gatekeepers to secondary care services in that country. EP was associated with older age, lower performance status, higher stage of disease, and certain histological sub-types such as small cell lung cancer. EP patients were less likely to receive a histologicl diagnosis, less likely to receive any anti-cancer treatment and if they did receive treatment it was less likely to be with curative intent. 76% of EP patients had significant medical co-morbidities. 59% presented with thoracic symptoms (dyspnea, chest/shoulder pain, cough, haemoptysis). The median length of inpatient stay was 14.31 days (range 0-68 days). Further comparative analysis between countries demonstrates the inter-country variation in patient demographics, presentation and management. Conclusions: The emergency route to lung cancer diagnosis is common across Europe, is associated with specific patient demographics, and represents a significant burden on acute services. The gatekeeper role of the GP does not appear to govern EP rates. Establishing the causes behind EP of lung cancer should allow identification, earlier diagnosis and better outcomes for this vulnerable patient population.
Corrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”
Authors: J.-C. Soria, F. DeBraud, R. Bahleda, B. Adamo, F. Andre, R. Dienstmann, A. Delmonte, R. Cereda, J. Isaacson, J. Litten, A. Allen, F. Dubois, C. Saba, R. Robert, M. D'Incalci, M. Zucchetti, M.G. Camboni, J. Tabernero
Journal: Annals of Oncology (2015)
Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).
Authors: Sandrine J. Faivre, Armando Santoro, Robin Katie Kelley, Philippe Merle, Ed Gane, Jean-Yves Douillard, Dirk Waldschmidt, Mary Frances Mulcahy, Charlotte Costentin, Beatriz Minguez, Pasqua Papappicco, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Nicola Murray, Karim A. Benhadji, Eric Raymond, Gianluigi Giannelli
Journal: Journal of Clinical Oncology (2013)

4118 Background: TGF-ß signaling is associated with HCC progression in moderate to poorly differentiated tumors overexpressing alpha-fetoprotein (AFP) levels. We report here the safety and antitumor activity of LY in HCC patients with elevated AFP in this ongoing study. Methods: Patients with advanced HCC who progressed on sorafenib (SF) or are ineligible to receive SF, advanced Child-Pugh A/B7 HCC, AFP ≥1.5x ULN, ECOG PS ≤1, measurable disease (RECIST 1.1), and ≤1 prior systemic regimen were eligible. LY was administered as intermittent dosing of 14 days on/14 days off (28 days =1 cycle). Patients were randomized to either 160 mg/day (Arm A) or 300 mg/day (Arm B) LY. Primary endpoints were time-to-progression (TTP) and biomarker changes (serum AFP, TGF-ß and E-cadherin) for each dose. Secondary endpoints included toxicity (CTCAE, V 4.0) and pharmacokinetics (PK). Results: 106 patients were enrolled (Arm A=37; B=69), including 92% non-Asians. Baseline characteristics were (Arm A/B): median age 61/66 years; PS=0 60/51%; Child-Pugh A 97/86%; etiology: hepatitis C 30/33%, hepatitis B 24/25%, alcohol 22/22%. Overall, 78/83% of patients had received prior SF; 64/58% of patients had AFP ≥400 ng/mL. Median TTP was 12.0 weeks (90% CI: 7.1, 12.6) in the overall population (Arm A, 12.6 weeks; Arm B, 10.9 weeks). In SF-naïve patients, TTP was 18.3 weeks (90% CI: 6.3-non-estimable). TTP was higher in the non-alcohol compared to alcohol-only etiology group (median 12.1 vs. 6.1 weeks). Median baseline serum TGF-ß1 was 3.4 ng/mL (range: 1.4-3.7) and E-cadherin was 6.1 mg/mL (range: 1.9-17.3). AFP decline of &gt;25% occurred in 21/106 patients (20%). Four patients discontinued treatment due to a drug-related AE. Most common grade 3/4 related AEs in patients were: neutropenia (n=3), GI bleeding (n=2), fatigue (n=2), and anemia (n=2). Preliminary PK analysis (51 patients) demonstrated moderate interpatient exposure variability (42%). Conclusions: Based on the manageable toxicity profile, the evidence for biomarker/TTP responses, and an analysis of the aggregate PK/PD data, the 300 mg/day dose was chosen for future studies in HCC. Clinical trial information: NCT01246986.
Central Nervous System Events In Patients with Diffuse Large B-Cell Lymphoma In the Rituximab Era
Authors: Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Saburo Tsunoda, Yasufumi Masaki, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Oshima, Yoshihiro Hatta, Yoshiyuki Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Yoshiaki Ishigatsubo, Kengo Takeuchi
Journal: Blood (2010)
CHANGE IN UTILIZATION TRENDS OF PERCUTANEOUS ATRIAL SEPTAL DEFECT CLOSURE POST 2008 ACC/AHA GUIDELINES FOR ADULTS WITH CONGENITAL HEART DISEASE
Authors: Siva Sagar Taduru, Shubha Deep Roy, Madhuri Ramakrishnan, Rakesh Ponnapureddy, Paramdeep Baweja
Journal: Journal of the American College of Cardiology (2017)
LEFT ATRIAL FUNCTION INDEX AS A PREDICTOR OF CARDIOVASCULAR DISEASE AND ATRIAL FIBRILLATION: DATA FROM THE FRAMINGHAM OFFSPRING STUDY
Authors: Mayank Sardana, Darleen Lessard, Nisha Parikh, Adedotun Ogunsua, Aditya Vaze, Gregory Nah, Susan Cheng, Randell Thomas, Gerard Aurigemma, Emelia Benjamin, Gary Mitchell, Vasan Ramachandran, Connie Tsao, Nelson Schiller, David McManus
Journal: Journal of the American College of Cardiology (2017)
Status of Early-Career Academic Cardiology
Authors: Carl W. Tong, Meena S. Madhur, Anne K. Rzeszut, Marwah Abdalla, Islam Abudayyeh, Erick Alexanderson, Jonathan Buber, Dmitriy N. Feldman, Rakesh Gopinathannair, Ravi S. Hira, Andrew M. Kates, Thorsten Kessler, Steve Leung, Satish R. Raj, Erica S. Spatz, Melanie B. Turner, Anne Marie Valente, Kristin West, Chittur A. Sivaram, Joseph A. Hill, Douglas L. Mann, Andrew M. Freeman
Journal: Journal of the American College of Cardiology (2017)
NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis.
Authors: Fernando Rivera, Paula Jiménez, Pilar Garcia Alfonso, Carlos Lopez, Javier Gallego, M. Luisa Limon, Maria Alsina, Luis Lopez-Gomez, Maica Galán, Esther Falco, Jose Luis Manzano, Encarnación González, Raquel Serrano, Eva Fernandez Parra, Monica Jorge
Journal: Journal of Clinical Oncology (2013)

4098 Background: Perioperative chemotherapy has demonstrated better OS and DFS than surgery alone in resectable stomach or EGJ adenocarcinoma. Trastuzumab has improved OS when added to chemotherapy in pts with HER-2 + metastatic gastric cancer and is interesting to explore its role in the perioperative setting. Methods: A Spanish, multicenter, open-label phase II study evaluated the efficacy and toxicity profile of perioperative XELOX-T (capecitabine 1000 mg/m2/12h po days 1-14, oxaliplatin 130 mg/m2 day 1, trastuzumab 8 mg/kg→ mg/kg day 1, q3w ; 3 preoperative cycles and 3 postsurgery cycles followed by 12 cycles of trastuzumab monotherapy) in patients with T1-2N+M0 or T3-4NxM0 resectable stomach or EGJ adenocarcinoma, HER-2+ ( IHQ3+ or IHQ2+/FISH+). The primary endpoint was 18 months DFS, secondary endpoint included pCR, R0 resection rate, ORR and toxicity of preoperative treatment (NCI CTC v3.0 criteria). Results: From June 2010 to March 2012, 36 pts were included: median age 65 (39-85); ECOG 0/1/2: 16/19/1 pts; localization: stomach 21 pts, EGJ 15 pts; histologic type: intestinal: 23 pts, diffuse: 4 pts, mixed: 1pt, not specified 8 pts; TNM: T 4: 7 pts; N+: 31 pts. Preoperative XELOX-T: Response: PR: 14 pts (39%), SD: 18 pts, PD: 0 pts, NE: 4 pts. G-3-4 toxicity (≥ 5% of pts): diarrhea 22% and asthenia 5%. Surgery was performed in 31 pts: R0: 28 pts (78%, 95% CI: 61-90%), R1: 1 pt, R2: 2 pts (1 had peritoneal carcinomatosis); pCR was observed in 7 pts (19 %; 95% CI: 8-36%) and 22 pts (61%) were pN0. Two pts died due to surgical complications,. We do not have mature data about postoperative XELOX-T yet. Follow-up is still too short for DFS and OS. Conclusions: This preliminary analysis suggests that perioperative XELOX+T in HER-2 positive resectable stomach or esophagogastric junction adenocarcinoma is feasible and has interesting activity. Clinical trial information: NCT01130337.
PERI-STRUT LOW INTENSITY AREA PREDICTS NEOINTIMAL PROGRESSION ASSOCIATED WITH LATE ENLARGEMENT OF SELF-EXPANDING NITINOL STENTS IN SUPERFICIAL FEMORAL ARTERIES: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Masayasu Ikutomi, Kozo Okada, Kojiro Miki, Ryo Kameda, Fumiyuki Otsuka, Paul Yock, Peter Fitzgerald, Osami Kawarada, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2017)
Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation - Initial Report of a Phase II Trial.
Authors: H. Jean Khoury, Mauricette Michallet, Selim Corm, Lydia Roy, Dan Jones, Andreas Hochhaus, Hagop Kantarjian, Annie-Claude Benichou, Richard Schwartz, Jorge Cortes
Journal: Blood (2007)
연구논문 : B형간염바이러스 감염과 췌장암 발생의 연관성에 관한 연구
Authors: 홍승권 ( Seung Goun Hong ), 김지훈 ( Ji Hoon Kim ), 이영선 ( Young Sun Lee ), 윤아일린 ( Eileen Yoon ), 이현정 ( Hyun Jung Lee ), 황진기 ( Jin Ki Hwang ), 정은석 ( Eun Suk Jung ), 주문경 ( Moon Kyung Joo ), 정영걸 ( Young Kul Jung ), 연종은 ( Jong Eun Yeon ), 박종재 ( Jong Jae P)
Journal: Clinical and Molecular Hepatology (2010)

목적: B형 및 C형간염바이러스 감염은 간세포암의 주요 위험인자이며, 간내담도암과 비호지킨 림프종의 발생에도 기여한다고 알려져 왔다. 최근 B형간염바이러스의 잠재감염이 있는 경우에 췌장암의 발생이 유의하게 높다는 보고가 있었다. 하지만 B형간염의 유병률이 높은 지역에서의 연구는 부족한 실정으로 한국과 같이 유병률이 높은 지역에서B형 및 C형간염바이러스 감염과 췌장암의 발생과 의 연관성에 대해 알아보고자 하였다. 대상 및 방법: 2003년 1월부터 2007년 12월까지 췌장암으로 진단받은 환자를 대상으로 하였고, 대조군은 그 기간 동안의 위암 환자를 대상으로 2배수의 환자를 진단 시 연령과 성별로 짝짓기하여 선정하였다. 췌장암과 위암의 진단은 조직학적 진단과 경우에 따라 영상학적 소견을 포함한 임상적 진단으로 이루어졌다. 이들의 혈청 HBsAg, anti-HCV의 양성 유무를 확인하였고, 혼란 변수의 보정을 위해 췌장암의 위험인자인 흡연, 음주, 당뇨, 만성 췌장염의 병력에 대해서도 조사하였다. 결과: 췌장암 환자는 506명이었으며 위암 환자는 1,008명으로 조직학적으로 진단된 경우는 각각 58.1%와 97.3%였다. 이들의 평균 나이는 각각 63.5±11.1세, 63.9±11.0세였고, 남녀비는 1.5:1로 연령과 성비에 차이를 보이지 않았다(P>0.05). 단변량 분석에서 HBsAg, anti-HCV양성, 당뇨, 흡연, 음주, 만성 췌장염의 병력에 대한 교차비(95% 신뢰구간)가 각각 0.90 (0.52-1.56; P=0.70), 1.87(0.87-4.01; P=0.11), 2.66(2.04-3.48; P<0.001), 2.30(1.83-2.90; P<0.001), 1.14(0.89-1.46; P=0.31), 4.40(1.66-11.66; P=0.003)이었고, 다변량 분석에서 췌장암 발생에 유의한 독립인자는 당뇨, 흡연, 만성 췌장염의 병력으로 교차비가 각각 2.67(2.00-3.56; P<0.001), 2.49(1.93-3.21; P<0.001), 4.60(1.56-13.53; P=0.006)이었다. 결론: 알려진 위험인자인 당뇨, 흡연, 만성 췌장염의 병력과 달리 HBsAg 및 anti-HCV 양성과 췌장암의 발생은 관련이 없었다. B형간염바이러스 유병률이 높은 지역에서 HBsAg 양성인 경우와 췌장암의 발생과의 관련성을 확인하기 위해 더 많은 연구가 필요할 것이다.
Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant
Authors: Ramzi Abboud, Michael Slade, Wenners Ballard, Jesse Keller, John F DiPersio, Peter Westervelt, Camille N. Abboud, Todd A Fehniger, Kathryn Trinkaus, Rizwan Romee
Journal: Blood (2016)
Niche-Based Screening Reveals Leukemia Stem Cell Specific Therapeutics
Authors: Kimberly A. Hartwell, Peter G. Miller, Alison L. Stewart, Alissa R. Kahn, David J. Logan, Joseph Negri, Mildred Duvet, Shrikanta Chattopadhyay, Sebastian Shterental, Lisa P Chu, Jae Hung Shieh, Marcus Jaeraas, Vladimir Dancik, Rajiv Narayan, Christina Huang, J Erika Haydu, Siddhartha Mukherjee, Alykhan F Shamji, Nicola J Tolliday, Anne E. Carpenter, Stuart L. Schreiber, Andrew M. Stern, Malcolm AS Moore, David T. Scadden, Benjamin L. Ebert, Todd R. Golub
Journal: Blood (2011)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Authors: QiWen Fan, Ozlem Aksoy, Robyn A. Wong, Shirin Ilkhanizadeh, Chris J. Novotny, William C. Gustafson, Albert Yi-Que Truong, Geraldine Cayanan, Erin F. Simonds, Daphne Haas-Kogan, Joanna J. Phillips, Theodore Nicolaides, Masanori Okaniwa, Kevan M. Shokat, William A. Weiss
Journal: Cancer Cell (2017)
Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer
Authors: D. J. Cohen, T. Ryan, T. Moskovits, N. Cazeau, E. Newman, H. L. Pachter, H. S. Hochster
Journal: Journal of Clinical Oncology (2009)

e15594 Background: The addition of E to G results in improved survival for patients(pts) with locally advanced and metastatic pancreatic cancer. Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF. Sorafenib, a multitargeted tyrosine kinase inhibitor which targets VEGR 1–3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize with these agents resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression and therefore improve outcome. Methods: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, ECOG PS 0–1, and adequate organ function were eligible and received G 1,000 mg/m 2 over 30 min weekly × 3 every 4 weeks. E 150 mg PO daily and S 400 mg PO bid were given continuously. CT scans were performed every 2 cycles (8 weeks). Endpoints included safety and tolerability of the novel combination, PFS at 4 months, response rate, and OS. Results: Between 9/07–12/08 19 pts were enrolled with a median age 59 (range 45- 75), M/F 13/6, PS (0/1) 14/5. All 19 had metastatic disease. 17 pts are evaluable for toxicity and efficacy. The median number of cycles on treatment was 2 (range 1–10). The most common grade (gr) 3 toxicities were thrombocytopenia (24%), venous thrombosis (12%), and hyperbilirubinemia (12%). The most common gr 4 toxicity was infection (12%). 1 pt each experienced gr 3 HFSR, gr 3 diarrhea, gr 3 bleeding (epistaxis) and 1 had a non-fatal bowel perforation. There was 1 PR and 6 SD for an overall RR of 6% and a DCR of 41%. Conclusions: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to gemcitabine alone, except for very manageable cutaneous reactions. Further follow up is required to determine the combination's efficacy, though some patients have achieved prolonged disease stabilization. Supported in part by grants from Bayer Healthcare Pharmaceuticals/Onyx and OSI. [Table: see text]
Taux de détection des adénomes lors des coloscopies du programme de dépistage organisé du cancer colorectal: nouveau test, nouveau standard
Authors: B Denis, F Arnold, J Botokeky, I Gendre, M Guerbaz, E Jafflin, C Morel, V Riviere-Simonet, MC Scandola-Guyot, P Perrin
Journal: Endoscopy (2017)

Tout programme d'amélioration de la qualité de la coloscopie intègre l'évaluation du rendement de l'endoscopiste. En France, seul le programme national de dépistage organisé du cancer colorectal (DO CCR) offre la population homogène permettant cette évaluation. Le rendement des coloscopies pour OC-Sensor positif est significativement supérieur à celui des coloscopies pour Hemoccult positif. Il est donc nécessaire d'actualiser les «standards» dans le cadre du nouveau programme français de DO CCR. Le but de cette étude était d'évaluer le rendement des endoscopistes dans le programme de DO CCR par OC-Sensor et de proposer de nouveaux standards.
Correction: ERBIN deficiency links STAT3 and TGF-β pathway defects with atopy in humans
Authors: J.J. Lyons, Y. Liu, C.A. Ma, X. Yu, M.P. O’Connell, M.G. Lawrence, Y. Zhang, K. Karpe, M. Zhao, A.M. Siegel, K.D. Stone, C. Nelson, N. Jones, T. DiMaggio, D.N. Darnell, E. Mendoza-Caamal, L. Orozco, J.D. Hughes, J. McElwee, R.J. Hohman, P.A. Frischmeyer-Guerrerio, M.E. Rothenberg, A.F. Freeman, S.M. Holland, J.D. Milner
Journal: The Journal of Experimental Medicine (2017)

Vol. 214, No. 3, March 2017. Pages [669–680][1].

The Journal of Experimental Medicine regrets that due to a production error, the original version of this paper does not display the correct values in the contour plots of [Fig. 5 (A and D)][2]. The legend remains correct, and the corrected figure
Expression of glucose-regulated protein 78 (GRP78) and its regulator microrna-181 during the development and progression of ovarian cancer.
Authors: Animesh Barua, Aparna Yellapa, Salvatore A Grasso, Jacques S Abramowicz, Sameer Sharma, Alfred S Guirguis, Sanjib Basu, Pincas Bitterman
Journal: Journal of Clinical Oncology (2013)

5579 Background: Ovarian cancer (OVCA) is a lethal malignancy of women with a distinct pattern of metastasis through peritoneal dissemination. Sustained exposure of the ovaries to oxidative stress due to inflammatory processes including ovulatory genotoxicity, makes the ovarian microenvironment conducive to malignant cell proliferation. GRP78 is a stress-inducible protein which resides in the endoplasmic reticulum of the cell. Thus GRP78 may be a marker of ovarian tumor associated stress and could represent a therapeutic target for OVCA. The goal of this study was to examine if GRP78 expression increases in association with OVCA development and determine the molecular mechanism of its increase in ovarian tumors. Methods: All tissues were collected from patients who underwent surgery and processed for immunohistochemistry (IHC), proteomic study (2D-WB) and miRNA expression. Expression of GRP78 was examined in paraffin sections of normal ovaries (n = 20), benign (serous cystadenoma, n = 15 and cystadenofibroma, n = 5) and ovaries with papillary serous carcinoma at early stage (n= 20 at stages I and II) and late stage (n = 20, stages III and IV) by IHC and confirmed by 2D-WB (representative samples). Changes in miRNA-181 (post-translation regulator of GRP78) expression were examined by qRT-PCR. Results: GRP78 expression by normal ovarian surface epithelium and epithelium of benign tumors was very weak. In contrast, the intensity of GRP78 expression was significantly (p&lt;0.05) high in early stage OVCA and increased further in late stage OVCA. An immunoreactive band of 78kDa detected by 2D-WB confirmed IHC observations. In contrast, expression of miRNA-181 by malignant tumors significantly (p&lt;0.05) decreased as the tumor progressed to late stages. Conclusions: The results of the present study suggest that GRP78 expression is associated with the development and progression of malignant ovarian tumors. Increase in GRP78 expression was associated with the down-regulation of miRNA-181. Expression of GRP78 by malignant ovarian epithelium represents a potential marker with usefulness for targeted drug delivery. Support: Elmer and Sylvia Sramek Foundation.
PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF CARDIAC TROPONIN-T ELEVATION IN PATIENTS ADMITTED WITH HYPERTENSIVE CRISES
Authors: Arthur Omondi, Pedro Villablanca Spinetto, Faraj Kargoli, Tatsiana Aleksandrovich, Peter Vlismas, Jean Claude Uwamungu, Tatiana Teslova, Daniel Sims
Journal: Journal of the American College of Cardiology (2017)
GERIATRIC ASSESSMENT TOOLS AND OUTCOME PREDICTION IN TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Clara Kwan, Melvyn Hecht, Sunday Olatunde, Antigone Hatzimihalis, Peter Homel, Paul Saunders, Gregory Crooke, Greg Ribakove, Robert Frankel, Jacob Shani
Journal: Journal of the American College of Cardiology (2017)
Focal Positivity for Non-Specific Esterase in AML: A Surrogate Marker to Predict AML with t(8;21)/RUNX1-RUNX1T1
Authors: Stefani Parmentier, Nicole Birninger, Uta Oelschlägel, Brigitte Mohr, Markus Schaich, Frank Kroschinsky, Christian Thiede, Gerhard Ehninger
Journal: Blood (2011)
A Comprehensive Geriatric Assessment Is More Effective Than Clinical Judgement to Prospectively Identify Elderly Patients with Diffuse Large Cell Lymphoma Who Can Tolerate Full-Dose Anthracyclin-Based Treatment and Achieve the Same Outcome as Young Patients.
Authors: Alessandra Tucci, Chiara Bottelli, Samantha Ferrari, Erika Borlenghi, Monica Drera, Giuseppe Rossi
Journal: Blood (2007)